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Introduction
Patients with chronic obstructive pulmonary disease (COPD) are at increased risk for 
cardiovascular disease (CVD). Those with moderate airflow limitation are more likely to 
die from CVD than respiratory failure (1). Arterial pulse wave velocity (aPWV), a 
vascular stiffness marker, is an independent predictor of CVD risk known to be elevated 
in COPD patients (2). Reduced arterial elasticity plays a direct pathologic role in 
promoting CVD events. Therefore, decreasing aPWV should lessen future morbidity 
and mortality. Previous studies addressing whether inhaled therapies for COPD reduce 
aPWV and adverse cardiovascular (CV) events showed inconclusive results (3–5), 
perhaps due to inadequate sample sizes or patients were at low CVD risk. The Study to 
Understand Mortality and Morbidity in COPD (SUMMIT) trial offered a unique study 
opportunity due to its large patient population and because all patients had a 
heightened CVD risk. In a pre-defined sub-study, we tested whether aPWV would 
predict mortality and if inhaled therapy would affect aPWV and several additional 
metrics of arterial stiffness.
Methods
Study Design
SUMMIT was a multicenter, randomized, double-blind, event-driven trial in 16,485 
patients (40–80 years) with moderate COPD (mean [±standard deviation {SD}] post-
bronchodilator forced expiratory volume in 1 s [FEV1] 60±6% predicted) who had, or 
were at high-risk (≥60 years with ≥2 risk factors) for, CVD (6). The primary endpoint was 
all-cause mortality (ACM); secondary endpoints were rate of post-bronchodilator FEV1 
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decline and an adjudicated on-treatment CV composite of myocardial infarction, 
unstable angina, stroke, transient ischemic attack and CV death.
Patients were randomized to once-daily: inhaled placebo (n = 591), long-acting 
Β2-agonist (LABA) (vilanterol 25 mcg [VI]; n = 583), corticosteroid (ICS) (fluticasone 
furoate [FF] 100 mcg; n = 601) or combination therapy (FF/VI; n = 584). 
An assessment of arterial stiffness (pulse wave analysis [PWA] and/or carotid-
femoral aPWV) were measured with the SphygmoCor (AtCor Medical Inc., Itasca, USA) 
device in a sub-study of 2,359 patients, of whom 1,788 had acceptable baseline aPWV, 
with annual measurements for up to 3 years.
The study was approved by local ethics committees and conducted in 
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Statistical Analysis
Change in aPWV was analyzed using a mixed model repeated measures analysis with 
fixed effect terms for age, sex, baseline aPWV, study treatment, visit and study 
treatment by visit. This model was repeated separately for patients with baseline aPWV 
<11 and ≥11 m/s. This threshold was selected based on published reference values 
demarcating elevation for patients of similar age (7). Similar analyses were performed 
on other PWA parameters including central augmentation pressure, or central systolic 
blood pressure.
Page 4 of 14
 AJRCCM Articles in Press. Published February 04, 2020 as 10.1164/rccm.201908-1639LE 
 Copyright © 2020 by the American Thoracic Society 
Cox proportional hazards analyses of time to death and time to first CV 
composite event were performed using patients divided into four groups based on their 
baseline aPWV measurements (quartiles split at 7.4 m/s, 8.8 m/s and 10.7 m/s).
Results
Demographics of the 2,359 patients in the sub-study were comparable to those of the 
SUMMIT intent-to-treat efficacy (ITT-E) population: 69% male, with mean±SD for age 
65±8 years, post-bronchodilator FEV1 60±6%, and 40±22 pack-year smoking history, 
with 49% current smokers. Seventy-two percent had CV disease; the remainder had ≥2 
CV risk factors in addition to their smoking history.
In the ITT-E population, ACM was unaffected by combination therapy (hazard 
ratio 0.88, 95% confidence interval [CI], 0.74–1.04; P = 0.14) or the individual 
components. For all treatment groups aPWV remained reasonably stable over the year 
following the baseline measurement (mean 9.14 m/s), with an overall change of 0.15 
m/s, (95% CI, 0.01–0.29 m/s). Conversely, the probability of ACM increased relative to 
baseline aPWV when presented as quartiles. Patients in the highest quartile group 
(aPWV >10.7 m/s) had a 90% increase (95% CI, -5–281%) in risk of death versus the 
lowest quartile group (PWV ≤7.4 m/s) (Figure 1). No relationship was found between 
aPWV and on-treatment CV composite. No treatment affected change in aPWV at 1 
year either overall (Figure 2), or when baseline aPWV was dichotomized at 11 m/sec 
(Table). Similarly, there was no treatment effect on PWA parameters: central 
augmentation pressure, central augmentation pressure at a heart rate of 75 bpm, or 
central systolic blood pressure.
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Discussion
In patients with COPD with moderate airflow limitation, with or at high-risk of CVD, 
baseline aPWV appeared predictive of mortality but was unaffected by therapy. Several 
studies report an association between impaired pulmonary function and adverse CV 
outcomes even after adjusting for accepted CV risk factors (8). Mechanisms underlying 
this association are currently unknown, however recent evidence suggests that 
systemic inflammation in COPD may promote atherosclerosis (9), supporting a 
pathogenetic link between these two conditions. Moreover, patients with COPD and 
biomarkers of persistent inflammation are at greater mortality risk (9). Increased aPWV 
has been shown to be a predictor of all-cause and CV morbidity and mortality (10) and 
has been shown to relate to COPD and emphysema severity (11).
ICS/LABA improve lung function and decrease COPD exacerbations. A post hoc 
analysis comparing fluticasone propionate/salmeterol with placebo suggested that the 
former regimen lowered aPWV at 12 weeks in patients with COPD and moderate airflow 
limitation (post-bronchodilator FEV1 55–56% predicted) with baseline aPWV values 
>10.9 m/s (3). Similarly, a non-placebo-controlled 12-week trial demonstrated that both 
FF/VI and tiotropium lowered aPWV by ~1 m/s in patients with COPD (post-
bronchodilator FEV1 46.5% predicted) with baseline values ≥11 m/s (4). However, a 
subsequent 24-week trial in patients (post-bronchodilator FEV1 50.1% predicted), mean 
baseline aPWV of 13.26 m/s, failed to demonstrate an effect of FF/VI on aPWV versus 
placebo and no relationship was observed on aPWV and hsCRP, fibrinogen, IL-6 or 
PARC (5).
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This analysis adds to and confirms previous studies evaluating the impact of 
treating COPD on co-morbid CV complications. The cumulative data suggest that 
despite the increased prevalence and importance of CVD disease in patients with 
COPD, aggressive treatment focusing on improving CVD risk factors is paramount, as 
inhaled therapy for COPD appears unlikely to reduce the associated heightened CV 
risk. Smoking is a common risk factor for both COPD and CVD. Future studies 
investigating smoking-induced inflammation may identify potential pathogenetic links 
between COPD and CVD, from which the knowledge gained might lead to the 
development of novel therapies.
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Figure Legends
Figure 1. Kaplan-Meier plot of time to on- or post-treatment death by pulse wave 
velocity quartiles. Reduction in risk, using Quartile group 1 as reference, calculated 
using Cox-proportional hazard ratios adjusted for age, sex, study treatment, ethnicity, 
race, BMI category, smoking status, cardiovascular study entry criteria, percent 
predicted FEV1, previous exacerbations, vascular and ischemic indicators and modified 
MRC dyspnea scale. Reduction in risk=(1-Hazard Ratio)*100.
Figure 2. Adjusted mean change from baseline aPWV over time by treatment category 
from mixed model repeated measures analysis. FF 100 = fluticasone furoate 100 mcg; 
aPWV = arterial pulse wave velocity; VI 25 = vilanterol 25 mcg.
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Table. Mixed Model Repeated Measures Analysis of Arterial Pulse Wave Velocity (m/s) 
at 1 year by Baseline Arterial Pulse Wave Velocity 
Placebo FF 100 VI 25 FF/VI 
100/25
Number of patients in arterial 
stiffness sub-study
591 601 583 584
Number of patients with baseline 
aPWV measurement
454 452 443 439
Patients with baseline aPWV <11 m/s 
Number of patients with data at 1 
year 
230 242 228 252
Baseline raw mean aPWV, m/s 8.2 8.2 8.0 8.1
Adjusted mean change in aPWV 
at 1 year, m/s
0.8 0.8 0.5 0.8
Patients with baseline aPWV ≥11 m/s 
Number of patients with data at 1 
year 
67 61 64 61
Baseline raw mean aPWV, m/s 13.1 12.8 12.9 13.1
Adjusted mean change in aPWV 
at 1 year, m/s
-2.2 -1.8 -2.0 -1.6
FF = fluticasone furoate; aPWV = arterial pulse wave velocity; VI = vilanterol.
There was little correlation of aPWV with any of the collected biomarkers (r values -
0.07–0.10; all P-values ≥0.095).
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Figure 1. Kaplan-Meier plot of time to on- or post-treatment death by pulse wave velocity quartiles. 
Reduction in risk, using Quartile group 1 as reference, calculated using Cox-proportional hazard ratios 
adjusted for age, sex, study treatment, ethnicity, race, BMI category, smoking status, cardiovascular study 
entry criteria, percent predicted FEV1, previous exacerbations, vascular and ischemic indicators and 
modified MRC dyspnea scale. Reduction in risk=(1-Hazard Ratio)*100. 
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Figure 2. Adjusted mean change from baseline aPWV over time by treatment category from mixed model 
repeated measures analysis. FF 100 = fluticasone furoate 100 mcg; aPWV = arterial pulse wave velocity; VI 
25 = vilanterol 25 mcg. 
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